Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE

Ségolène Hescot,Véronique Debien,Julien Hadoux,Delphine Drui,Magalie Haissaguerre,Christelle de la Fouchardiere,Delphine Vezzosi,Christine Do Cao,Rossella Libé,Christophe Le Tourneau,Eric Baudin,Christophe Massard,Pauline du Rusquec

European Journal of Cancer（2023）

引用 0|浏览7

暂无评分

摘要

•This study describes the inclusions in early clinical trials of ACC patients.•Cohort of 27 patients enroled in 30 early clinical trials.•Median PFS was 3.02 months with a disease control rate of 61%.•Median GMI was 1.32, with a significantly prolonged PFS in 52% as compared to previous line.•ACC patients may benefit from inclusion in early clinical trials in second line.

查看译文

关键词

Adrenocortical carcinoma,Early clinical trial,GMI,RMH score

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要